New pain drug tested with HIV pill in healthy volunteers

NCT ID NCT07570069

Ongoing Knowledge-focused Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This early-stage study is testing how a new pain medication called suzetrigine interacts with efavirenz, a drug used to treat HIV. The trial involves 18 healthy adults and measures how the body processes suzetrigine when taken alone versus with efavirenz. The goal is to check for any safety issues or changes in drug levels, not to treat pain directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Suzetrigine (also called SUZ, Journavx) and efavirenz
What this could lead to: If successful, this study could help doctors understand how to safely combine suzetrigine with other drugs that affect the same liver enzymes.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels and safety, not whether suzetrigine works for pain. Results may not apply to people with medical conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN

Contacts and locations

Locations

ICON - Utah - Salt Lake City Office

Salt Lake City, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.